The latest round of data on the 2011 Census shows that the country is exhibiting distinct signs of trading up as material living conditions improve for large sections of the population. Although this aggregate picture is not uniform across the country, analysts believe that the upward material mobility in society is creating the basis of a new consumer boom in the economy—serving up a perfect backdrop ahead of the presentation of...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

-The Hindu As it stands on the threshold of the Twelfth Plan, India has a historic opportunity to elevate education and healthcare as the strongest pillars of its future development. Yearning for life-building education is unprecedented today. Yet, as Amartya Sen pointed out last year, the system remains deeply unjust. Access to excellence is open to those who can afford it, while the less-affluent majority has been left behind without even...

-PTI An additional investment of Rs 1,15,660 crore would be required to revitalise the agriculture sector and boost production to meet the foodgrains demand under the proposed Food law, Parliament was informed today.  "To effectively implement the proposed Food Security Act, it is estimated that there should be an additional production of about 70-75 million tonnes of foodgrains," Minister of State for Agriculture Harish Rawat said in a written reply to Lok...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...